Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Boundless Bio Inc's Business Segments
Boundless Bio Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Member
Total Revenue
-
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Member0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Member | - | - |
Annual Results
Revenue Share by Reportable Segment - FY
- Member0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Member | - | - |
Description of Boundless Bio Inc
Audentes Therapeutics Inc is a biotechnology company that focuses on the development and commercialization of gene therapy products for serious and rare diseases. The company was founded in 2012 and is headquartered in San Francisco, California.
Audentes Therapeutics is primarily involved in the development of innovative gene therapies to address genetic disorders that currently have no cure or limited treatment options. The company's approach involves the delivery of functional copies of genes directly into patient cells, aiming to correct the underlying genetic mutations causing the disease.
The company's gene therapy platform utilizes adeno-associated virus (AAV) vectors as delivery tools. AAV vectors are small, non-pathogenic viruses that have been used successfully in clinical trials for many genetic diseases. Audentes Therapeutics focuses on optimizing the efficiency and safety of AAV vectors to ensure successful delivery and long-term expression of therapeutic genes in target cells.
Audentes Therapeutics has a broad pipeline of gene therapy candidates targeting different genetic disorders. These disorders include neuromuscular diseases like X-linked myotubular myopathy (XLMTM), Pompe disease, Duchenne muscular dystrophy (DMD), and myotonic dystrophy type 1 (DM1).
Their lead product candidate, AT132, is being developed for the treatment of XLMTM, which is a severe and rare genetic muscle disorder. The therapy aims to restore the production of a protein called myotubularin, which is necessary for muscle cell function and survival. AT132 has shown promising results in clinical trials, with improvements observed in muscle function tests and survival rates in patients.
In addition to AT132, Audentes Therapeutics has other gene therapies in various stages of development. AT845, for example, is being developed for the treatment of Pompe disease, which is a rare and progressive muscle disorder caused by the deficiency of an enzyme called acid alpha-glucosidase (GAA). The therapy aims to restore GAA enzyme activity and improve muscle function in patients.
To support their research and development efforts, Audentes Therapeutics collaborates with academic institutions, biotechnology companies, and contract manufacturing organizations. They also actively engage with patient advocacy groups and regulatory agencies to advance the development and commercialization of their gene therapies.
Overall, Audentes Therapeutics Inc is dedicated to revolutionizing the treatment of rare genetic diseases through the development of effective and safe gene therapies. Their approach could potentially provide transformative therapeutic options for patients with limited treatment choices and improve their quality of life.
Audentes Therapeutics is primarily involved in the development of innovative gene therapies to address genetic disorders that currently have no cure or limited treatment options. The company's approach involves the delivery of functional copies of genes directly into patient cells, aiming to correct the underlying genetic mutations causing the disease.
The company's gene therapy platform utilizes adeno-associated virus (AAV) vectors as delivery tools. AAV vectors are small, non-pathogenic viruses that have been used successfully in clinical trials for many genetic diseases. Audentes Therapeutics focuses on optimizing the efficiency and safety of AAV vectors to ensure successful delivery and long-term expression of therapeutic genes in target cells.
Audentes Therapeutics has a broad pipeline of gene therapy candidates targeting different genetic disorders. These disorders include neuromuscular diseases like X-linked myotubular myopathy (XLMTM), Pompe disease, Duchenne muscular dystrophy (DMD), and myotonic dystrophy type 1 (DM1).
Their lead product candidate, AT132, is being developed for the treatment of XLMTM, which is a severe and rare genetic muscle disorder. The therapy aims to restore the production of a protein called myotubularin, which is necessary for muscle cell function and survival. AT132 has shown promising results in clinical trials, with improvements observed in muscle function tests and survival rates in patients.
In addition to AT132, Audentes Therapeutics has other gene therapies in various stages of development. AT845, for example, is being developed for the treatment of Pompe disease, which is a rare and progressive muscle disorder caused by the deficiency of an enzyme called acid alpha-glucosidase (GAA). The therapy aims to restore GAA enzyme activity and improve muscle function in patients.
To support their research and development efforts, Audentes Therapeutics collaborates with academic institutions, biotechnology companies, and contract manufacturing organizations. They also actively engage with patient advocacy groups and regulatory agencies to advance the development and commercialization of their gene therapies.
Overall, Audentes Therapeutics Inc is dedicated to revolutionizing the treatment of rare genetic diseases through the development of effective and safe gene therapies. Their approach could potentially provide transformative therapeutic options for patients with limited treatment choices and improve their quality of life.
Audentes Therapeutics Inc. is a pioneering biotechnology company focused on the development and commercialization of genetic medicines specifically designed to address rare and serious diseases. The company utilizes advanced techniques and transformational gene therapy methodologies to provide innovative treatments that can significantly enhance the lives of affected patients. Below is a detailed description of the companys segments, products, and services.
Segments
1. Gene Therapy:
- This is the primary focus of Audentes Therapeutics. Gene therapy involves the introduction, removal, or alteration of genetic material within a patients cells to treat or prevent disease. Audentes specializes in therapies that target the root causes of genetic disorders through the delivery of healthy copies of defective genes.
- The technologies utilized often include adeno-associated viruses (AAVs), which are engineered to safely deliver therapeutic genes to the appropriate tissues in the body, aiming for long-term efficacy and safety.
Products
Audentes Therapeutics has developed several promising product candidates now at various stages of clinical and preclinical development. The following are their key product candidates:
1. AT132 (X-Linked Myotubular Myopathy):
- AT132 is the lead gene therapy candidate designed to treat X-Linked Myotubular Myopathy (XLMTM), a severe neuromuscular disorder caused by mutations in the MTM1 gene. This therapy aims to introduce a functional version of the MTM1 gene into the patients muscle cells. Positive preliminary data suggest an improvement in muscle function and strength in patients.
2. AT342 (Crigler-Najjar Syndrome):
- AT342 targets Crigler-Najjar Syndrome, a rare inherited disorder characterized by the inability to properly metabolize bilirubin due to mutations in the UGT1A1 gene, leading to high levels of bilirubin in the bloodstream. The therapy aims to deliver a functioning UGT1A1 gene, potentially normalizing bilirubin levels and preventing severe complications associated with the condition.
3. AT845 (Pompe Disease):
- AT845 is being developed for Pompe Disease, a genetic disorder caused by the deficiency of the GAA gene, leading to harmful accumulation of glycogen. The treatment focuses on delivering a functional GAA gene, aiming to enhance glycogen metabolism and improve muscle strength and function in affected patients.
4. AT307 (CASQ1 Sulfite Oxidase Deficiency):
- This gene therapy is designed to address CASQ1 sulfite oxidase (SOX) deficiency, a rare metabolic disorder caused by mutations in the CASQ1 gene. The goal of AT307 is to restore normal sulfite oxidase activity by delivering a functional CASQ1 gene, potentially alleviating associated metabolic derangements.
5. Other Products:
- Audentes has a robust pipeline that also includes additional gene therapy candidates, which may target conditions such as Duchenne Muscular Dystrophy (DMD), myotonic dystrophy type 1, and others. These candidates are in various stages of research and preclinical development, reflecting the company’s commitment to expanding its therapeutic reach.
Services
1. Clinical Trials:
- Audentes Therapeutics conducts extensive clinical trials to evaluate the safety and efficacy of their gene therapy products. These trials follow rigorous protocols and involve multiple phases to assess how well the therapies work in diverse patient populations while ensuring stringent safety standards.
2. Patient Support Programs:
- The company may provide a range of patient support services, which can include educational resources, access to medical professionals, and guidance for navigating the healthcare landscape. These initiatives aim to support patients and their families in managing the complexities associated with rare diseases and clinical trial participation.
3. Collaborations and Partnerships:
- Audentes Therapeutics actively engages in strategic collaborations with other pharmaceutical companies, academic institutions, and regulatory agencies. These partnerships are designed to enhance research capabilities, streamline product development processes, and facilitate access to broader resources and expertise within the biotechnology and healthcare sectors.
Conclusion
Audentes Therapeutics Inc. is at the forefront of genetic medicine, leveraging advanced gene therapy technologies to develop treatments for rare and serious diseases. With an extensive product pipeline and dedicated patient services, the company aims to transform the landscape for patients with underserved medical needs, striving to improve their quality of life through innovative genetic interventions.
Segments
1. Gene Therapy:
- This is the primary focus of Audentes Therapeutics. Gene therapy involves the introduction, removal, or alteration of genetic material within a patients cells to treat or prevent disease. Audentes specializes in therapies that target the root causes of genetic disorders through the delivery of healthy copies of defective genes.
- The technologies utilized often include adeno-associated viruses (AAVs), which are engineered to safely deliver therapeutic genes to the appropriate tissues in the body, aiming for long-term efficacy and safety.
Products
Audentes Therapeutics has developed several promising product candidates now at various stages of clinical and preclinical development. The following are their key product candidates:
1. AT132 (X-Linked Myotubular Myopathy):
- AT132 is the lead gene therapy candidate designed to treat X-Linked Myotubular Myopathy (XLMTM), a severe neuromuscular disorder caused by mutations in the MTM1 gene. This therapy aims to introduce a functional version of the MTM1 gene into the patients muscle cells. Positive preliminary data suggest an improvement in muscle function and strength in patients.
2. AT342 (Crigler-Najjar Syndrome):
- AT342 targets Crigler-Najjar Syndrome, a rare inherited disorder characterized by the inability to properly metabolize bilirubin due to mutations in the UGT1A1 gene, leading to high levels of bilirubin in the bloodstream. The therapy aims to deliver a functioning UGT1A1 gene, potentially normalizing bilirubin levels and preventing severe complications associated with the condition.
3. AT845 (Pompe Disease):
- AT845 is being developed for Pompe Disease, a genetic disorder caused by the deficiency of the GAA gene, leading to harmful accumulation of glycogen. The treatment focuses on delivering a functional GAA gene, aiming to enhance glycogen metabolism and improve muscle strength and function in affected patients.
4. AT307 (CASQ1 Sulfite Oxidase Deficiency):
- This gene therapy is designed to address CASQ1 sulfite oxidase (SOX) deficiency, a rare metabolic disorder caused by mutations in the CASQ1 gene. The goal of AT307 is to restore normal sulfite oxidase activity by delivering a functional CASQ1 gene, potentially alleviating associated metabolic derangements.
5. Other Products:
- Audentes has a robust pipeline that also includes additional gene therapy candidates, which may target conditions such as Duchenne Muscular Dystrophy (DMD), myotonic dystrophy type 1, and others. These candidates are in various stages of research and preclinical development, reflecting the company’s commitment to expanding its therapeutic reach.
Services
1. Clinical Trials:
- Audentes Therapeutics conducts extensive clinical trials to evaluate the safety and efficacy of their gene therapy products. These trials follow rigorous protocols and involve multiple phases to assess how well the therapies work in diverse patient populations while ensuring stringent safety standards.
2. Patient Support Programs:
- The company may provide a range of patient support services, which can include educational resources, access to medical professionals, and guidance for navigating the healthcare landscape. These initiatives aim to support patients and their families in managing the complexities associated with rare diseases and clinical trial participation.
3. Collaborations and Partnerships:
- Audentes Therapeutics actively engages in strategic collaborations with other pharmaceutical companies, academic institutions, and regulatory agencies. These partnerships are designed to enhance research capabilities, streamline product development processes, and facilitate access to broader resources and expertise within the biotechnology and healthcare sectors.
Conclusion
Audentes Therapeutics Inc. is at the forefront of genetic medicine, leveraging advanced gene therapy technologies to develop treatments for rare and serious diseases. With an extensive product pipeline and dedicated patient services, the company aims to transform the landscape for patients with underserved medical needs, striving to improve their quality of life through innovative genetic interventions.